Long-acting therapies offer value for chronic disease, improving adherence and outcomes. This OHE report highlights HTA gaps, ...

Q1 2025 Earnings Conference Call May 9, 2025 4:30 PM ET. Company Participants. Bernie Hertel - Head of Investor Relations Punit Dhillon - Presi ...

Sustained-release naltrexone may slightly increase illicit opioid use and serious adverse events compared to opioid agonists, with uncertain effects on retention and acceptability. It may reduce ...

Metformin and SGLT2 inhibitors are associated with similar rates of incident gout among patients with type 2 diabetes.

Articles ...